154 related articles for article (PubMed ID: 10689511)
1. Immunological surrogate markers of disease activity in multiple sclerosis.
Kieseier BC; Giovannoni G; Hartung HP
Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():570-83. PubMed ID: 10689511
[No Abstract] [Full Text] [Related]
2. [Differential diagnosis of multiple sclerosis and systemic vasculitis].
Pizova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(10):4-8. PubMed ID: 15553371
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in multiple sclerosis: role of antibodies.
Berger T; Reindl M
Dis Markers; 2006; 22(4):207-12. PubMed ID: 17124342
[TBL] [Abstract][Full Text] [Related]
4. [Biomarkers in multiple sclerosis (a review and experimental data)].
Vorob'eva AA; Ivanova MV; Fominykh VV; Zakharova MN; Zigangirova NA; Guliaeva NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):23-31. PubMed ID: 24416809
[TBL] [Abstract][Full Text] [Related]
5. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis.
Giovannoni G; Kieseier B; Hartung HP
J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S31-6. PubMed ID: 9647282
[TBL] [Abstract][Full Text] [Related]
6. Immunological indicators of disease activity and prognosis in multiple sclerosis.
Galboiz Y; Miller A
Curr Opin Neurol; 2002 Jun; 15(3):233-7. PubMed ID: 12045718
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
Sormani MP
Mult Scler; 2017 Mar; 23(3):378-381. PubMed ID: 28260416
[TBL] [Abstract][Full Text] [Related]
8. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.
van Oosten BW; Barkhof F; Scholten PE; von Blomberg BM; Adèr HJ; Polman CH
Arch Neurol; 1998 Jun; 55(6):793-8. PubMed ID: 9626770
[TBL] [Abstract][Full Text] [Related]
9. Biological markers for multiple sclerosis.
Lutterotti A; Berger T; Reindl M
Curr Med Chem; 2007; 14(18):1956-65. PubMed ID: 17691938
[TBL] [Abstract][Full Text] [Related]
10. Definition of non-responders: biological markers.
Furlan R
Neurol Sci; 2008 Sep; 29 Suppl 2():S214-5. PubMed ID: 18690495
[TBL] [Abstract][Full Text] [Related]
11. [Immunological markers of disease activity in the course of 2-CDA treatment of multiple sclerosis].
Michałowska-Wender G; Tokarz-Kupczyk E; Losy J; Sniatała-Kamasa M; Wender M
Neurol Neurochir Pol; 1999; 33(4):749-56. PubMed ID: 10612090
[TBL] [Abstract][Full Text] [Related]
12. Development of biomarkers in multiple sclerosis.
Bielekova B; Martin R
Brain; 2004 Jul; 127(Pt 7):1463-78. PubMed ID: 15180926
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in multiple sclerosis.
Housley WJ; Pitt D; Hafler DA
Clin Immunol; 2015 Nov; 161(1):51-8. PubMed ID: 26143623
[TBL] [Abstract][Full Text] [Related]
14. Immunological patterns identifying disease course and evolution in multiple sclerosis patients.
Furlan R; Rovaris M; Martinelli Boneschi F; Khademi M; Bergami A; Gironi M; Deleidi M; Agosta F; Franciotta D; Scarpini E; Uccelli A; Zaffaroni M; Kurne A; Comi G; Olsson T; Filippi M; Martino G
J Neuroimmunol; 2005 Aug; 165(1-2):192-200. PubMed ID: 15949850
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of pediatric multiple sclerosis.
Vargas-Lowy D; Chitnis T
J Child Neurol; 2012 Nov; 27(11):1394-407. PubMed ID: 22952316
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis.
Berger T
Autoimmunity; 2004 Jun; 37(4):321-4. PubMed ID: 15518051
[No Abstract] [Full Text] [Related]
17. Immunological markers in multiple sclerosis: tackling the missing elements.
Rinaldi L; Gallo P
Neurol Sci; 2005 Dec; 26 Suppl 4():S215-7. PubMed ID: 16388362
[TBL] [Abstract][Full Text] [Related]
18. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
Hegen H; Bsteh G; Berger T
Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
[TBL] [Abstract][Full Text] [Related]
19. Inflammation-related plasma and CSF biomarkers for multiple sclerosis.
Huang J; Khademi M; Fugger L; Lindhe Ö; Novakova L; Axelsson M; Malmeström C; Constantinescu C; Lycke J; Piehl F; Olsson T; Kockum I
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12952-12960. PubMed ID: 32457139
[TBL] [Abstract][Full Text] [Related]
20. Antimyelin antibodies with no progression to multiple sclerosis.
Pelayo R; Tintoré M; Montalban X; Rovira A; Espejo C; Reindl M; Berger T
N Engl J Med; 2007 Jan; 356(4):426-8. PubMed ID: 17251547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
